0.27
price up icon1.12%   0.003
after-market Handel nachbörslich: .27
loading
Schlusskurs vom Vortag:
$0.267
Offen:
$0.26
24-Stunden-Volumen:
1.15M
Relative Volume:
0.27
Marktkapitalisierung:
$8.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.71M
KGV:
-0.0231
EPS:
-11.71
Netto-Cashflow:
$-18.24M
1W Leistung:
+19.42%
1M Leistung:
-15.36%
6M Leistung:
-70.03%
1J Leistung:
-86.29%
1-Tages-Spanne:
Value
$0.247
$0.2727
1-Wochen-Bereich:
Value
$0.2187
$0.2727
52-Wochen-Spanne:
Value
$0.2023
$3.97

Genprex Inc Stock (GNPX) Company Profile

Name
Firmenname
Genprex Inc
Name
Telefon
512-537-7997
Name
Adresse
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Name
Mitarbeiter
15
Name
Twitter
@genprex
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
GNPX's Discussions on Twitter

Vergleichen Sie GNPX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
GNPX
Genprex Inc
0.27 8.89M 0 -22.71M -18.24M -11.71
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Genprex Inc Stock (GNPX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-01-26 Eingeleitet National Securities Buy
2019-04-29 Eingeleitet Noble Capital Markets Outperform

Genprex Inc Aktie (GNPX) Neueste Nachrichten

pulisher
Jun 11, 2025

Genprex Enters $12.5M Stock Purchase Agreement - TipRanks

Jun 11, 2025
pulisher
Jun 11, 2025

Genprex (GNPX) Announces Plan to Sell 15 Million Shares | GNPX Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Genprex Files for Resale of 15 Million Shares - MarketScreener

Jun 11, 2025
pulisher
Jun 10, 2025

genprex regains nasdaq compliance but faces bid price challenge By Investing.com - Investing.com Nigeria

Jun 10, 2025
pulisher
Jun 09, 2025

genprex regains nasdaq compliance but faces bid price challenge - Investing.com

Jun 09, 2025
pulisher
Jun 05, 2025

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting - mx.advfn.com

Jun 05, 2025
pulisher
Jun 05, 2025

Genprex (NASDAQ:GNPX) Shares Down 2.8% – Should You Sell? - Defense World

Jun 05, 2025
pulisher
Jun 03, 2025

Genprex to Participate at BIO 2025 International Convention - BioSpace

Jun 03, 2025
pulisher
Jun 03, 2025

Genprex to Participate at BIO 2025 International Convention | GN - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Genprex to Participate at BIO 2025 International Convention | GNPX Stock News - GuruFocus

Jun 03, 2025
pulisher
May 29, 2025

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting | GNPX Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting - Nasdaq

May 29, 2025
pulisher
May 28, 2025

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting | GNPX Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Genprex (GNPX) Reports Promising Preclinical Data for Diabetes Gene Therapy | GNPX Stock News - GuruFocus

May 28, 2025
pulisher
May 24, 2025

What Can Genprex Inc (NASDAQ: GNPX) Expect In 2025? - Stocksregister

May 24, 2025
pulisher
May 14, 2025

WestPark Capital Leads Placement for GNPX | GNPX Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Genprex (GNPX) to Release Quarterly Earnings on Wednesday - Defense World

May 14, 2025
pulisher
May 10, 2025

Things To Consider Before Buying Genprex Inc (NASDAQ: GNPX) - Stocksregister

May 10, 2025
pulisher
May 08, 2025

Genprex and University of Pittsburgh sign new agreement to study GPX-002 for diabetes - BioWorld MedTech

May 08, 2025
pulisher
May 07, 2025

Attention Investors: What’s Really Going On With Genprex Inc (NASDAQ: GNPX) - Stocksregister

May 07, 2025
pulisher
May 07, 2025

Genprex Announces Research Agreement for Diabetes Therapy - TipRanks

May 07, 2025
pulisher
May 07, 2025

Genprex (GNPX) Advances Diabetes Therapy Research with New Agreement | GNPX Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes | GNPX Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes - PR Newswire

May 07, 2025
pulisher
May 06, 2025

Genprex (GNPX) Secures Exclusive Patent License for Gene Therapy - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Genprex (GNPX) Secures Exclusive Patent License for Gene Therapy | GNPX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Genprex Secures Exclusive Patent License for Reqorsa - TipRanks

May 06, 2025
pulisher
May 06, 2025

Genprex Signs Exclusive License to Additional Gene Therapy Techn - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma | GNPX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma - PR Newswire

May 06, 2025
pulisher
May 05, 2025

Geode Capital Management LLC Grows Position in Genprex, Inc. (NASDAQ:GNPX) - Defense World

May 05, 2025
pulisher
May 02, 2025

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions - ADVFN

May 02, 2025
pulisher
May 02, 2025

Genprex collaborators report positive preclinical data on the use of Reqorsa gene therapy at the 2025 AACR Annual Meeting - SelectScience

May 02, 2025
pulisher
Apr 30, 2025

Genprex Inc (NASDAQ: GNPX) Is The Number One Stock Currently Moving. - Stocksregister

Apr 30, 2025
pulisher
Apr 30, 2025

Genprex (GNPX) Showcases Promising Results for Reqorsa Gene Ther - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Genprex Collaborators Report Positive Preclinical Data On The Use Of Reqorsa Gene Therapy - TradingView

Apr 30, 2025
pulisher
Apr 30, 2025

Genprex Collaborators Report Positive Preclinical Data on the Us - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Financial Metrics Check: Genprex Inc (GNPX)’s Ratios for Trailing Twelve Months - DWinneX

Apr 30, 2025
pulisher
Apr 30, 2025

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting - PR Newswire

Apr 30, 2025
pulisher
Apr 29, 2025

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting - The Malaysian Reserve

Apr 29, 2025
pulisher
Apr 29, 2025

Genprex Collaborators to Present Positive Preclinical Data on Di - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Taking the lead: Genprex Inc (GNPX) - Sete News

Apr 29, 2025
pulisher
Apr 29, 2025

Understanding the Risks of Investing in Genprex Inc (GNPX) - knoxdaily.com

Apr 29, 2025
pulisher
Apr 29, 2025

Revolutionary Gene Therapy Could Transform Diabetes Treatment: New Primate Study Reveals Promising Results - Stock Titan

Apr 29, 2025
pulisher
Apr 29, 2025

Genprex (GNPX) Secures Exclusive Patent License for Mesothelioma - GuruFocus

Apr 29, 2025
pulisher
Apr 28, 2025

Indo-Asian News Service - Indo-Asian News Service (IANS)

Apr 28, 2025
pulisher
Apr 28, 2025

Genprex secures exclusive license for mesothelioma gene therapy By Investing.com - Investing.com South Africa

Apr 28, 2025
pulisher
Apr 28, 2025

Genprex secures exclusive license for mesothelioma gene therapy - Investing.com Australia

Apr 28, 2025
pulisher
Apr 28, 2025

Choosing between riding the trend or protecting profits: Genprex Inc (GNPX) - uspostnews.com

Apr 28, 2025
pulisher
Apr 28, 2025

Genprex Inc (NASDAQ: GNPX) Stock’s Potential for Success in the Coming Months - Marketing Sentinel

Apr 28, 2025

Finanzdaten der Genprex Inc-Aktie (GNPX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):